The US Food and Drug Administration (FDA) Food Disaggregation Database (FDA-FDD): a new tool for US dietary exposure assessment

被引:0
|
作者
Spungen, Judith H. [1 ]
Shimizu, Miyuki [1 ]
Jarman, Dwayne [1 ]
Farakos, Sofia M. Santillana [1 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, Off Analyt & Outreach, Div Risk & Decis Anal, College Pk, MD 20740 USA
关键词
Contaminants; dietary exposure; food composition; food consumption; total diet study;
D O I
10.1080/19440049.2024.2393789
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Dietary exposure to a food chemical (e.g. contaminant, nutrient, or other natural constituent) is a function of the concentration of the chemical in foods and the quantity of each food consumed. Exposures to food chemicals can be estimated using intake data from What We Eat in America (WWEIA), the food consumption survey portion of the National Health and Nutrition Examination Survey (NHANES). To estimate exposures to chemicals in foods consumed by NHANES/WWEIA respondents, the consumption data must be mapped to chemical concentration data on the same or similar foods. However, food chemical data are generally not available on all the foods and food mixtures that are reported in NHANES/WWEIA. To address this, we developed the FDA Food Disaggregation Database (FDA-FDD), a 'recipe' database with estimates of ingredient percentages. FDA-FDD allows mapping to food chemical data based on ingredients in NHANES/WWEIA foods rather than on food mixtures, resulting in more accurate exposure estimates. Using FDA-FDD, FDA mapped over 11,000 NHANES/WWEIA foods to FDA's Total Diet Study (TDS) foods. FDA-FDD is available as part of a publicly available interactive application that also allows access to the TDS mapping.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] US Food and Drug Administration's (FDA) safety assessment of food ingredients
    Thurmond, Scott
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [3] US Food and Drug Administration (FDA) to conduct a review of the safety of orlistat
    Idris, Iskandar
    [J]. DIABETES OBESITY & METABOLISM, 2009, 11 (11): : 1089 - 1089
  • [4] Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)
    White, Nicholas J.
    Watson, James A.
    Simpson, Julie A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 75 (02) : 358 - 358
  • [5] Review times for ophthalmic new drug applications (NDAs) at the US Food and Drug Administration (FDA).
    Novack, GD
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1997, 38 (04) : 1346 - 1346
  • [7] Comparison of drug approval between health Canada (HC) and the US Food and Drug Administration (FDA).
    Ezeife, Doreen Anuli
    Tang, Patricia
    Heng, Daniel Yick Chin
    Welch, Stephen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Utility of a US Food and Drug Administration (FDA) label indication for condoms for anal sex
    Siegler, Aaron J.
    Ahlschlager, Lauren
    Rosenthal, Elizabeth M.
    Sullivan, Patrick S.
    Kelley, Colleen F.
    Rosenberg, Eli S.
    Sanchez, Travis H.
    Moore, Renee H.
    Mehta, C. Christina
    Cecil, Michael P.
    [J]. SEXUAL HEALTH, 2020, 17 (01) : 91 - 95
  • [9] Paxlovid™ Information From US Food & Drug Administration (FDA) and Guidance for AES Members
    Cokley, Jon A.
    Gidal, Barry E.
    Keller, Joy A.
    Vossler, David G.
    [J]. EPILEPSY CURRENTS, 2022, 22 (03) : 201 - 204
  • [10] Anaphylactoid reactions to dextran 40 and 70: Reports to the US Food and Drug Administration (FDA)
    Zinderman, Craig E.
    Landow, Laurence Landow
    Wise, Robert P.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S115 - S116